Image
Tom Davenport
Tom Davenport co-founder of the International Institute for Analytics and author of “The AI Advantage: How to Put the Artificial Intelligence Revolution to Work” said companies that have been most successful in using AI to their advantage are taking smaller steps, rather than embarking on large-scale projects.
“In general, I believe that these less ambitious AI projects are more likely to be successful than the really dramatic moonshots,” Davenport said. “AI does small things very well, it doesn’t do big tasks nearly as well.”
Davenport spoke about the current state of AI’s use in business at an event hosted by the Hartford-based Travelers Institute, the public policy and educational arm of property-casualty insurer Travelers Cos. At the event, which also featured Travelers Executive Vice President and Chief Technology and Operations Officer Mojgan Lefebvre, Davenport differentiated useful AI business applications from high-tech hype.
Descubren nueva terapia para vencer el tumor cerebral omnia.com.mx - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from omnia.com.mx Daily Mail and Mail on Sunday newspapers.
Credit: UC Berkeley
The NFT for Jim Allison’s Nobel Prize-winning invention was minted on May 27 and will go up for auction next week on Foundation, an Ethereum platform.
Most of us will never win a Nobel Prize, but the University of California, Berkeley, is offering everyone the opportunity to purchase the next best thing: nonfungible tokens (NFTs) for the patent disclosures at the heart of two Nobel Prize-winning inventions from the university’s research labs.
The NFTs link to online digitized documents internal forms and correspondence that document the initial research findings that led to two of the most important biomedical breakthroughs of the 21st century: CRISPR-Cas9 gene editing, for which UC Berkeley’s Jennifer Doudna shared the 2020 Nobel in Chemistry; and cancer immunotherapy, for which James Allison shared the 2018 Nobel in Physiology or Medicine. UC Berkeley will continue to own the relevant patents.